Robin Snellings
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robin Snellings has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Audrene Edwards
Baylor Scott & White Medical Center Research Institute, Temple, Texas, USA
1 shared publication- Collin Telchik
Department of Internal Medicine, Baylor Scott & White Medical Center , Temple, Texas
1 shared publication Juan Negron-Diaz
Division of Infectious Disease, Baylor Scott & White Medical Center – Temple, Temple, Texas, USA
1 shared publication- Lizbeth Cahuayme-Zuniga
Department of Internal Medicine, Division of Infectious Diseases, University of Michigan, Ann Arbor, Michigan
1 shared publication - Phi Tran
Department of Gastroenterology, Baylor Scott & White Medical Center, Temple, TX
1 shared publication
Latest Publications
- 27 September 2024
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (1) , 21-25
A 5-year single-center review of Strongyloides seropositivity in kidney transplant candidates in Central Texas
Strongyloides stercoralis is a soil-transmitted helminth that can lead to life-threatening hyperinfection in transplant recipients. Targeted screening based on social history alone may preclude a large proportion of seropositive patients. Our institution implemented universal screening for kidney transplant candidates. This study aimed to identify the prevalence and identify risk factors of transplant candidates. This was a retrospective chart review of kidney transplant candidates who were Strongyloides seropositive using the Strongyloides IgG enzyme-linked immunosorbent assay (ELISA) test. An equivocal Strongyloides serology was defined as 1.0 to 1.1 IV, a positive test as >1.1 IV, and a negative test as Strongyloides, and 121 (7.3%) tested positive. Forty-seven patients (38.8%) who tested positive had no reported travel history to endemic areas, and 86% of patients originated from the United States. Forty-six patients (97.9%) who received a kidney transplant received treatment with ivermectin, and none developed disseminated disease or hyperinfection. Among kidney transplant candidates screened for Strongyloides, 7.3% were seropositive and many reported no travel history to endemic areas, which highlights the significant prevalence of this parasite in Central Texas. Universal screening at our institution identified a substantial number of seropositive patients who might have otherwise been missed.
- 27 September 2024
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (1) , 21-25
A 5-year single-center review of Strongyloides seropositivity in kidney transplant candidates in Central Texas
Strongyloides stercoralis is a soil-transmitted helminth that can lead to life-threatening hyperinfection in transplant recipients. Targeted screening based on social history alone may preclude a large proportion of seropositive patients. Our institution implemented universal screening for kidney transplant candidates. This study aimed to identify the prevalence and identify risk factors of transplant candidates. This was a retrospective chart review of kidney transplant candidates who were Strongyloides seropositive using the Strongyloides IgG enzyme-linked immunosorbent assay (ELISA) test. An equivocal Strongyloides serology was defined as 1.0 to 1.1 IV, a positive test as >1.1 IV, and a negative test as Strongyloides, and 121 (7.3%) tested positive. Forty-seven patients (38.8%) who tested positive had no reported travel history to endemic areas, and 86% of patients originated from the United States. Forty-six patients (97.9%) who received a kidney transplant received treatment with ivermectin, and none developed disseminated disease or hyperinfection. Among kidney transplant candidates screened for Strongyloides, 7.3% were seropositive and many reported no travel history to endemic areas, which highlights the significant prevalence of this parasite in Central Texas. Universal screening at our institution identified a substantial number of seropositive patients who might have otherwise been missed.